Follow the Parabilis Medicines, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €4.8bn. The latest transaction was filed on 22 July 2026 (Acquisition). Among the most active insiders: Flynn James E. Every trade is openly available.
15
Insider Decl.
n/a
Thresholds
€6m
6 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Parabilis Medicines, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$41.75.
32Σ signal
Buys €6mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
407,132 sharesVoting Common StockSEC:0001193805-26-000798:7
15 of 15 declarations
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. is a biotechnology company focused on developing innovative treatments for serious diseases. It is listed on the XNAS market.